ConductScience.org, home
Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma
API referenceFor AI assistants

Trial · NCT02911142

Participant flow17

How many started, completed or left each group, period by period.

1 to 17 of 17

Download this page as JSON
PeriodMilestoneGroupParticipantsUnits counted
Phase I - Safety & TolerabilitySTARTEDLenalidomide+Etoposide Phosphate, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin & Rituximab6
Phase I - Safety & TolerabilityReceived Specified DoseLenalidomide+Etoposide Phosphate, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin & Rituximab6
Phase I - Safety & TolerabilityUnderwent Screening/StagingLenalidomide+Etoposide Phosphate, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin & Rituximab6
Phase I - Safety & TolerabilityEvaluated for ResponseLenalidomide+Etoposide Phosphate, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin & Rituximab6
Phase I - Safety & TolerabilityOff TreatmentLenalidomide+Etoposide Phosphate, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin & Rituximab6
Phase I - Safety & TolerabilityOff StudyLenalidomide+Etoposide Phosphate, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin & Rituximab6
Phase I - Safety & TolerabilityDisease Progression on StudyLenalidomide+Etoposide Phosphate, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin & Rituximab1
Phase I - Safety & TolerabilityCOMPLETEDLenalidomide+Etoposide Phosphate, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin & Rituximab5
Phase I - Safety & TolerabilityNOT COMPLETEDLenalidomide+Etoposide Phosphate, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin & Rituximab1
Phase II - Recommended Phase 2 DoseSTARTEDLenalidomide+Etoposide Phosphate, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin & Rituximab11
Phase II - Recommended Phase 2 DoseReceived Specified DoseLenalidomide+Etoposide Phosphate, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin & Rituximab11
Phase II - Recommended Phase 2 DoseEvaluated for ResponseLenalidomide+Etoposide Phosphate, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin & Rituximab11
Phase II - Recommended Phase 2 DoseOff TreatmentLenalidomide+Etoposide Phosphate, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin & Rituximab11
Phase II - Recommended Phase 2 DoseOff StudyLenalidomide+Etoposide Phosphate, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin & Rituximab11
Phase II - Recommended Phase 2 DoseDisease Progression on StudyLenalidomide+Etoposide Phosphate, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin & Rituximab3
Phase II - Recommended Phase 2 DoseCOMPLETEDLenalidomide+Etoposide Phosphate, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin & Rituximab7
Phase II - Recommended Phase 2 DoseNOT COMPLETEDLenalidomide+Etoposide Phosphate, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin & Rituximab4

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT02911142/flow

API referenceFor AI assistants